Myriad Genetics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MYGN and other ETFs, options, and stocks.

About MYGN

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments.

CEO

Paul J. Diaz

CEOPaul J. Diaz

Employees

2,700

Employees2,700

Headquarters

Salt Lake City, Utah

HeadquartersSalt Lake City, Utah

Founded

1991

Founded1991

Employees

2,700

Employees2,700

MYGN Key Statistics

Market cap

1.66B

Market cap1.66B

Price-Earnings ratio

-5.78

Price-Earnings ratio-5.78

Dividend yield

—

Dividend yield—

Average volume

541.63K

Average volume541.63K

High today

$18.69

High today$18.69

Low today

$18.25

Low today$18.25

Open price

$18.42

Open price$18.42

Volume

238.03K

Volume238.03K

52 Week high

$24.21

52 Week high$24.21

52 Week low

$13.82

52 Week low$13.82

MYGN News

Yahoo Finance 2d

Nearly Half of Americans Say They've Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight ... - Yahoo Finance

Myriad Genetics, Inc. 80% of people diagnosed with anxiety, depression report losing years or decades of time SALT LAKE CITY, April 17, 2024 (GLOBE NEWSWIRE)...

TipRanks 3d

Myriad Genetics announces new study published in Prenatal Diagnosis

Myriad Genetics announced that Prenatal Diagnosis has published a study demonstrating exceptional positive predictive value for 22q11.2 microdeletion screening...

Yahoo Finance 3d

New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 ... - Yahoo Finance

Myriad Genetics, Inc. SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medi...

Analyst ratings

46%

of 13 ratings

Buy

30.8%

Hold

46.2%

Sell

23.1%